StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
95
This month
1
This week
1
This year
2
Publishing Date
2023 - 02 - 09
1
2023 - 02 - 01
1
2023 - 01 - 23
1
2023 - 01 - 10
1
2022 - 12 - 19
1
2022 - 10 - 26
1
2022 - 10 - 17
1
2022 - 09 - 29
1
2022 - 08 - 30
1
2022 - 08 - 23
1
2022 - 08 - 09
1
2022 - 07 - 05
1
2022 - 06 - 29
1
2022 - 06 - 21
1
2022 - 06 - 09
1
2022 - 05 - 25
1
2022 - 05 - 24
1
2022 - 05 - 03
1
2022 - 04 - 27
1
2022 - 04 - 06
2
2022 - 04 - 01
1
2022 - 03 - 31
1
2022 - 03 - 14
1
2022 - 03 - 01
1
2022 - 02 - 16
1
2022 - 02 - 10
1
2022 - 02 - 01
1
2022 - 01 - 12
1
2022 - 01 - 04
1
2021 - 12 - 22
1
2021 - 12 - 21
1
2021 - 12 - 13
1
2021 - 12 - 10
2
2021 - 11 - 19
1
2021 - 11 - 15
1
2021 - 11 - 02
1
2021 - 10 - 25
1
2021 - 09 - 23
1
2021 - 09 - 15
1
2021 - 09 - 03
1
2021 - 08 - 23
1
2021 - 08 - 17
1
2021 - 08 - 10
1
2021 - 07 - 14
1
2021 - 05 - 20
1
2021 - 05 - 18
1
2021 - 04 - 29
3
2021 - 04 - 15
1
2021 - 04 - 14
1
2021 - 03 - 30
1
2021 - 03 - 09
1
2021 - 03 - 05
1
2021 - 02 - 23
1
2021 - 02 - 18
1
2021 - 02 - 09
1
2021 - 01 - 13
1
2021 - 01 - 11
1
2021 - 01 - 06
1
2020 - 12 - 15
1
2020 - 11 - 30
1
Sector
Communications
1
Health technology
95
Tags
Agreement
3
Alliances
3
Animal
2
Application
11
Approval
7
Approved
3
Biotech-bay
9
Breast
3
Breast cancer
3
Cancer
19
Candidate
4
Care
2
China
2
Clinical-trials-phase-ii
2
Clinical-trials-phase-iii
3
Commercial
2
Commercialization
4
Conference
6
Covid
4
Crofelemer
41
Day
2
Designation
9
Diarrhea
45
Disease
8
Distribution
2
Drug
29
Europe
3
Family
4
Fda
15
Funding
3
Grants
2
Health
58
Initiated
5
License
5
Life
2
Merge
2
Microvillus
3
N/a
71
Np-300
3
Orphan drug
3
Patent
4
Pharmaceuticals
5
Phase 2
4
Potential
3
Pre-clinical
2
Preclinical
2
Presentation
9
Rare
4
Research
9
Spac
3
Store
3
Study
4
Submission
3
Symposium
2
Syndros
2
Therapy
13
Treatment
17
Trial
7
Veterinarians
2
Veterinary
4
Entities
3m company
156
Abb ltd
220
Abbott laboratories
287
Abbvie inc.
235
Alphabet inc.
141
Amgen inc.
116
Apple inc.
192
Arrival
715
Astellas pharma inc
103
Astrazeneca plc
119
Bank of montreal
183
Becton, dickinson and company
122
Bnp paribas
150
Bristol-myers squibb company
186
Broadcom inc.
105
Canadian imperial bank of commerce
116
Chicken soup for the soul entertainment, inc.
134
Cisco systems, inc.
201
Diana shipping inc.
131
Duke energy corporation
116
Eli lilly and company
410
Ericsson
276
Firstenergy corp.
109
Gartner, inc.
381
General electric company
151
Gilead sciences, inc.
110
Glaxosmithkline plc
145
Honeywell international inc.
254
Hubspot, inc.
220
Incyte corporation
154
Infineon technologies ag
106
Intel corporation
183
Johnson & johnson
811
Kering
169
Koninklijke philips n.v.
118
Lithium corp
142
Medtronic plc
246
Merck & company, inc.
143
Microsoft corporation
189
Morgan stanley
464
Nec corp
109
Novartis ag
198
Nvidia corporation
130
Oracle corporation
203
Orange
1246
Panasonic corp
112
Pfizer, inc.
200
Pool corporation
106
Regeneron pharmaceuticals, inc.
144
Royal bank of canada
136
Sanofi
902
Sap se
256
Snowflake inc.
117
Takeda pharmaceutical company limited
119
Telus corporation
104
Teva pharmaceutical industries ltd
152
Thermo fisher scientific inc
267
Trimble inc.
105
Verizon communications inc.
203
Whirlpool corporation
105
Symbols
FNCTF
1
JAGX
95
Exchanges
Nasdaq
95
Crawled Date
2023 - 02 - 01
1
2023 - 01 - 23
1
2023 - 01 - 10
1
2022 - 12 - 19
1
2022 - 10 - 26
1
2022 - 10 - 17
1
2022 - 09 - 29
1
2022 - 08 - 30
1
2022 - 08 - 23
1
2022 - 08 - 09
1
2022 - 07 - 05
1
2022 - 06 - 29
1
2022 - 06 - 21
1
2022 - 06 - 09
1
2022 - 05 - 25
1
2022 - 05 - 24
1
2022 - 05 - 07
1
2022 - 04 - 30
1
2022 - 04 - 09
1
2022 - 04 - 06
1
2022 - 04 - 02
1
2022 - 03 - 31
1
2022 - 03 - 19
1
2022 - 03 - 05
1
2022 - 02 - 19
1
2022 - 02 - 12
1
2022 - 02 - 01
1
2022 - 01 - 16
1
2022 - 01 - 05
1
2021 - 12 - 25
1
2021 - 12 - 22
1
2021 - 12 - 13
1
2021 - 12 - 11
1
2021 - 12 - 10
1
2021 - 11 - 20
1
2021 - 11 - 15
1
2021 - 11 - 02
1
2021 - 10 - 25
1
2021 - 09 - 23
1
2021 - 09 - 19
1
2021 - 09 - 03
1
2021 - 08 - 23
1
2021 - 08 - 17
1
2021 - 08 - 10
1
2021 - 07 - 14
1
2021 - 05 - 20
1
2021 - 05 - 18
1
2021 - 04 - 29
3
2021 - 04 - 15
1
2021 - 04 - 14
1
2021 - 03 - 30
1
2021 - 03 - 09
1
2021 - 03 - 05
1
2021 - 02 - 23
1
2021 - 02 - 18
1
2021 - 02 - 09
1
2021 - 01 - 13
1
2021 - 01 - 11
1
2021 - 01 - 06
1
2020 - 12 - 23
2
Crawled Time
00:20
1
01:00
1
11:00
1
12:00
2
12:15
1
12:20
5
12:30
4
13:00
32
13:08
1
13:15
1
13:20
2
13:33
1
14:00
12
14:08
2
14:11
2
14:12
2
14:20
1
14:30
2
15:00
3
16:20
11
17:31
2
18:00
1
19:00
1
20:00
1
20:20
1
21:00
2
Source
jaguarhealth.gcs-web.com
71
www.biospace.com
24
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
for
entities :
Jaguar health, inc.
save search
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published:
2024-04-16
(Crawled : 14:00)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
51.52%
|
O:
26.26%
H:
73.2%
C:
18.87%
health
cancer
care
for
commercial
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Published:
2024-02-12
(Crawled : 14:30)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
115.05%
|
O:
6.09%
H:
7.88%
C:
0.68%
fda
drug
diarrhea
health
designation
application
crofelemer
submission
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
Published:
2023-12-11
(Crawled : 20:00)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-32.13%
|
O:
-15.16%
H:
1.78%
C:
-18.62%
diarrhea
cancer
trial
therapy
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Published:
2023-12-06
(Crawled : 14:30)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-44.44%
|
O:
0.03%
H:
1.67%
C:
-1.27%
breast
health
life
symposium
cancer
pharmaceuticals
family
study
Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
Published:
2023-11-02
(Crawled : 14:00)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-48.2%
|
O:
1.7%
H:
3.0%
C:
-9.45%
rare
health
license
revenue
pharmaceuticals
commercialization
crofelemer
agreement
store
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Published:
2023-11-01
(Crawled : 14:00)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-47.98%
|
O:
1.45%
H:
1.57%
C:
-1.0%
patent
health
treatment
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
Published:
2023-10-18
(Crawled : 13:00)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-46.6%
|
O:
-4.27%
H:
8.4%
C:
5.92%
drug
conference
association
care
pharmaceuticals
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
Published:
2023-09-26
(Crawled : 13:00)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-33.33%
|
O:
0.19%
H:
3.51%
C:
-2.33%
life
cancer
pharmaceuticals
study
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
Published:
2023-09-21
(Crawled : 12:00)
- biospace.com/
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-37.06%
|
O:
-0.28%
H:
4.8%
C:
2.03%
health
research
adhd
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Published:
2023-09-13
(Crawled : 12:30)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-46.89%
|
O:
-0.71%
H:
3.71%
C:
-6.39%
patent
japan
health
treatment
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Published:
2023-09-12
(Crawled : 12:30)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-45.45%
|
O:
4.52%
H:
0.0%
C:
-1.74%
np-300
drug
candidate
institute
diarrhea
health
application
family
funding
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
Published:
2023-09-11
(Crawled : 12:30)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-47.04%
|
O:
0.03%
H:
0.0%
C:
-2.94%
conference
health
presentation
growth
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
Published:
2023-08-30
(Crawled : 12:30)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-55.91%
|
O:
-2.28%
H:
0.5%
C:
-4.94%
rare
disease
crofelemer
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Published:
2023-08-17
(Crawled : 12:20)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-66.48%
|
O:
-4.06%
H:
0.41%
C:
-2.97%
diarrhea
health
cancer
treatment
family
crofelemer
trial
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Published:
2023-08-09
(Crawled : 12:20)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-69.99%
|
O:
0.85%
H:
0.84%
C:
-10.4%
np-300
drug
candidate
diarrhea
health
application
family
funding
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Published:
2023-08-08
(Crawled : 13:00)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-70.19%
|
O:
-0.66%
H:
0.0%
C:
0.0%
fda
drug
disease
health
microvillus
treatment
application
crofelemer
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Published:
2023-08-07
(Crawled : 13:00)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-69.64%
|
O:
1.2%
H:
3.33%
C:
0.63%
diarrhea
breast
cancer
crofelemer
study
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Published:
2023-08-01
(Crawled : 13:00)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-72.27%
|
O:
1.02%
H:
0.67%
C:
-2.84%
fda
drug
diarrhea
health
treatment
application
crofelemer
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published:
2023-07-26
(Crawled : 12:20)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-68.71%
|
O:
2.57%
H:
11.58%
C:
6.27%
diarrhea
health
approval
treatment
trial
Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease
Published:
2023-06-28
(Crawled : 13:00)
- jaguarhealth.gcs-web.com
JAGX
|
$0.158
-10.79%
-12.09%
30M
|
Health Technology
|
-63.27%
|
O:
-0.53%
H:
6.69%
C:
6.28%
fda
drug
disease
health
microvillus
application
← Previous
1
2
3
4
5
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.